Explore key findings from two AHA 2026 abstracts using NCDR registry data.

OAC After LAAO

Kamil Faridi, MD, MS, et al., found that long-term oral anticoagulation (OAC) use after transcatheter left atrial appendage occlusion (LAAO) was low with reinitiation of the therapy infrequent. They included 53,984 Medicare patients (mean age 77 years, 43.2% women) captured by ACC's LAAO Registry from 2016 to 2021 who received a Watchman device. At two years, person-time spent off OAC was associated with lower total major bleeding rates (4.91 vs. 16.15 events per 100 person-years; adjusted odds ratio 0.29, 95% CI 0.27-0.31; p<0.001). Read more.

PCI and tMCS Use in Patients With Ischemic Cardiomyopathy

Including 84,704 patients (mean age 69.7 years, 74.8% male) from ACC's CathPCI Registry, Sachit Singal, MD, et al., determined that both PCI and temporary mechanical circulatory support (tMCS) volumes in patients with ischemic cardiomyopathy have increased from 2018 to 2025. Results showed that Impella microaxial flow pumps were the most common tMCS device used (72%). Over 7% of patients evaluated experienced in-hospital mortality, with rates higher in women, patients with diabetes and patients with LVEF <20%. Read more.

Interested in using the NCDR to test your hypotheses? The ACC is seeking research proposals for consideration for NCDR funding. Proposals should include hypothesis-driven research based on secondary analysis of NCDR data with the intent to develop manuscripts for peer-reviewed publication. Explore newly updated research resources, proposal requirements and submission guidance and submit your proposal by Feb. 12, 2027.

Clinical Topics: Anticoagulation Management, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention

Keywords: AHA Annual Scientific Sessions, AHA26, LAAO Registry, CathPCI Registry, National Cardiovascular Data Registries, Percutaneous Coronary Intervention, Atrial Appendage, Diabetes Mellitus, Cardiomyopathies, Anticoagulants